A brief description of the Lao version of ivonib (ivitinib) medication guidelines

The Lao version of ivonib (ivitinib), an isocitrate dehydrogenase-1 (IDH1) inhibitor, provides a new treatment option for many cancer patients. It is particularly suitable for adult patients with IDH1 mutations, including newly diagnosed adult patients with acute myeloid leukemia (AML) who are 75 years of age or older and have comorbidities that preclude intensive induction chemotherapy, as well as adult patients with relapsed or refractory AML, myelodysplastic syndromes (MDS), and previously treated locally advanced or metastatic cholangiocarcinoma. When using this medication, it is important to strictly follow your doctor's prescription and medication guidelines.

When taking ivosidenib, patients should make sure to swallow the tablets whole and avoid crushing, chewing or breaking them, as this may affect the effectiveness of the medicine. The usual dose is 500 mg once daily with food or alone. For patients with AML or MDS, if disease progression or unacceptable toxicity does not occur, it is recommended to continue using ivonib for at least 6 months to ensure sufficient clinical response time.

During the medication process, patients need to take the medication at the same time every day, regardless of whether it is taken with food or not. It is important not to change your dosage or stop taking it unless specifically directed by your doctor. At the same time, you should drink plenty of liquids when taking ivonib, but avoid taking it with high-fat foods at the same time to avoid affecting the absorption of the drug.

If a patient accidentally vomits shortly after taking ivonib, they should avoid taking additional doses and continue with the next dose as planned. If a dose is missed, it should be taken as soon as possible, but if the next dose is due within 12 hours, the missed dose should be skipped and avoid taking two doses within 12 hours.

In addition, ivonib may cause some adverse reactions, such as irregular heartbeat, stomach pain, nausea, vomiting, loss of appetite, diarrhea, constipation, etc. If symptoms of discomfort occur, seek medical attention immediately.

In short, the Lao version of ivonib provides an affordable treatment option for patients with IDH1 mutations. However, correct medication administration and precautions are crucial to ensure drug efficacy and patient safety. Therefore, patients should read the medication guide or instructions in detail before use and strictly follow the doctor's prescription and medication recommendations.

Reference materials:https://www.drugs.com/pro/tibsovo.html#S12.3